Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021

Excerpt from the Press Release:

Phase 2a Tolerability and Efficacy Data Supports Further Clinical Development of Samuraciclib in Combination with Fulvestrant in HR+, HER2- Breast Cancer Previously Treated with a CDK4/6 Inhibitor

DUBLIN, Ireland and BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) — Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today presented encouraging initial clinical data on samuraciclib (CT-7001), an oral and first-in-class inhibitor of CDK7, at the 2021 European Society of Medical Oncology (ESMO) Congress.

Data presented from a Phase 2a study of samuraciclib in combination with fulvestrant in women with hormone receptor positive (HR+), HER2- advanced breast cancer (BC) previously treated with a CDK4/6 inhibitor (abstract: 1346 (265P)) demonstrated clinical activity and tolerability that supports further clinical development of the combination.

“Today, for the first time, we presented data from a clinical trial of our oral CDK7 inhibitor, samuraciclib. Results of the Phase 2a study in combination with fulvestrant demonstrated clinical activity and tolerability in patients with HR+, HER2- advanced breast cancer, reinforcing our conviction that samuraciclib has potential to be a first and best-in-class treatment,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics. “As a reminder, the FDA recently granted Fast Track designation to samuraciclib in combination with fulvestrant for CDK4/6 inhibitor resistant patients. This patient population is particularly difficult to treat, with a recent trial showing only 8 weeks mPFS benefit when women are treated with fulvestrant alone. Based on this initial data, we believe samuraciclib has the potential to provide a clinically meaningful benefit for all patients, most notably in those women that are TP53 wildtype. In addition to fulvestrant, we are exploring additional samuraciclib combinations, including with giredestrant, a next-generation oral SERD, through our recently announced clinical collaboration with Roche in metastatic breast cancer. We thank the women that participated in this Phase 2a trial and look forward to continuing the fight against this and other types of cancer.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release